Companies › iTeos Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Inupadenant (EOS100850) Adenosine 2A receptor antagonist | ADORA2A | Phase 2 | Metastatic NSCLC - Non-Small Cell Lung Cancer | – |
| EOS301984 IKAROS degrader | – | Phase 1 | Advanced Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05403385 | Inupadenant (EOS100850) | Phase 2 | Metastatic NSCLC - Non-Small Cell Lung Cancer | Oncology | Jun 2025 |
| NCT06547957 | EOS301984 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2025 |
Arcus Biosciences TJ Biopharma Gilead Sciences RDC Clinical Zhejiang Vimgreen Pharmaceuticals GE Healthcare Innolake Biopharm AstraZeneca
Can-Fite BioPharma Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) TJ Biopharma ALX Oncology Shanghai EpimAb Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.